

PRESS RELEASE

Freezing of stem cells for osteoarthritis now available

Sydney, Australia – 12 April 2013

Regenerative medicine company, Regeneus, and cryogenic storage specialists, Cryosite Limited (ASX: CTE), have completed the development of a procedure for storing a patient's regenerative stem cells from fat. Now when a patient has a HiQCell® procedure, a stem cell therapy treatment for osteoarthritis, the additional cells can be stored as a patient's own "biobank" for future injections.

Steve Barbera, Commercial Development Director, Human Health at Regeneus, said, "We are very pleased by this partnership to be able to offer patients the option to store some of their own cells to be used for future treatment. Our cryopreservation offering will initially be available to patients of Dr Diana Robinson MBBS FACSP and her sports physician colleagues at Sydney Sportsmed Specialists, with deployment across other medical facilities and HiQCell licensed practitioners over the course of the next several months."

Regeneus works with sports physicians and orthopedic surgeons to conduct the HiQCell treatment, which involves harvesting a patient's adipose (fat) tissue and, after separating and concentrating the regenerative cells, injecting them in osteoarthritis-affected joints such as the knees, hips and ankles of that patient. The HiQCell treatment procedure is done under the supervision of the treating medical specialist.

Cryopreservation will be available only when a patient has a HiQCell procedure in an accredited medical facility. A proportion of the cells from the tissue extraction procedure will be prepared by a Regeneus technician and cryogenically stored by Cryosite under liquid nitrogen as low as -196°C. The stored cells can be held for an indefinite period of time until required for a future injection by the medical practitioner for future osteoarthritis treatment. Regeneus has developed assays (analytic procedures) to ensure the viability of the cells after freezing and before future re-injection.

Mr Graeme Moore, Executive Director at Cryosite, said, "We are pleased to partner with Regeneus in utilising our specialised capabilities in cryopreservation and cellular therapies for the further application of the HiQCell treatment".

Dr Diana Robinson, a leading sport and exercise physician and pioneer in the clinical development of the HiQCell procedure, is providing medical supervisory expertise in the development of the cryopreservation protocol and is conducting the first cryopreserved treatments. Dr Robinson said she "is pleased to be involved in this further development as it will offer additional patient benefits over a protracted timeframe."

The added benefits of cryopreservation with the HiQCell procedure includes, further improved medical outcomes, greater convenience and cost effectiveness. It will also open up the opportunity for Regeneus to work with medical specialists who wish to explore using HiQCell to treat other medical conditions including neuropathic pain that might be well suited to a more regular course of injections.

END

For more information contact:

Clare Serafini
Communications Manager, Regeneus Ltd
T: +61 2 9499 8010
E: clare.serafini@regeneus.com.au or go to www.regeneus.com.au

Graeme Moore
Executive Director, Cryosite
T: +61 2 8865 2000
E: graeme.moore@cryosite.com or go to www.cryosite.com

Dr Diana Robinson MBBS FACSP
Specialist Sports and Exercise Physician, Sydney Sportsmed Specialists
T: +61 2 9231 0102
E: info@sydney sportsmed specialists.com.au or go to www.sportsdoc.com.au

About Regeneus:

Regeneus is a Sydney-based regenerative medicine company that develops and commercialises proprietary technologies for the preparation of in-clinic and off-the-shelf cell therapies using adipose (fat)-derived regenerative cells including mesenchymal stem cells for the treatment of musculoskeletal and other inflammatory conditions in humans and animals.

About Cryosite:

Cryosite (ASX: CTE) is an Australian biotech company that has provided specialised Bio-repository, Clinical Trials Logistics, private Cord Blood Banking, and Cellular Therapies manufacturing services since 2002. Cryosite's facilities are NATA accredited (ISO15189) and its Cord Blood Stem Cell cryopreservation and storage laboratories are licensed by the TGA.